Despite a weak market, some stocks are seeing momentum, moving up on high volumes. These include pharma companies, which are gaining as the rupee fall make products more competitive in the global market. Natco Pharma (which is in 13 stock screeners) is one such gainer.

Natco Pharma has been a gainer on strong momentum in drug approvals by the FDA in the US market. Natco has built a strong portfolio of generics in the US and India, and in FY18, Natco's top four performers in the US have been the generic versions of Copaxone, Tamiflu, Doxorubicin and Lanthanum Carbonate. Copaxone should hold steady revenues for Natco in the coming quarters, as it is relatively difficult to copy. 

Also among the gainers are Shilpa Medicare, and pacgaking company Varun Beverages. For the full stock screener, click here.